LncRNAs and CircRNAs in cancer

被引:24
作者
Yin, Xin [1 ,2 ]
Lin, Huiran [3 ]
Lin, Lei [1 ]
Miao, Lei [1 ]
He, Jing [1 ]
Zhuo, Zhenjian [1 ,4 ]
机构
[1] Guangzhou Med Univ, Guangzhou Inst Pediat, Dept Pediat Surg,Guangzhou Women & Childrens Med, Guangdong Prov Key Lab Res Struct Birth Defect Di, 9 Jinsui Rd, Guangzhou 510623, Guangdong, Peoples R China
[2] Jinan Univ, Coll Pharm, Guangzhou, Guangdong, Peoples R China
[3] Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China
[4] Peking Univ, Lab Anim Ctr, Sch Chem Biol & Biotechnol, Shenzhen Grad Sch, Shenzhen, Peoples R China
来源
MEDCOMM | 2022年 / 3卷 / 02期
基金
中国国家自然科学基金;
关键词
cancer; circRNAs; lncRNAs; neuroblastoma; LONG NONCODING RNA; PROMOTES CELL-PROLIFERATION; INHIBITS NEUROBLASTOMA PROGRESSION; HEALTH-ORGANIZATION CLASSIFICATION; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIOMA-CELLS; GASTRIC-CANCER; WILMS-TUMOR; BREAST-CANCER;
D O I
10.1002/mco2.141
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is well known that noncoding RNAs (ncRNAs) cannot encode proteins, but they can play important regulatory roles in tumors by combining with proteins, RNAs, and DNAs. As more and more studies reveal the important roles and underlying mechanisms of long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) in cancer, their huge application potential in cancer therapy cannot be ignored. For example, lncRNAs can be involved in tumor-related signal transduction pathways, cell cycle control, DNA damage, epigenetic regulation, and microRNA control. A group of studies confirmed that abnormal expression of lncRNAs can affect cancer progression. Furthermore, as covalently closed continuous circular ncRNAs, many recent studies have shown that circRNAs have regulatory effects and other important biological significances in cancer. Interestingly, circRNAs were found to have translational functions. This has greatly attracted people's attention to circRNAs research. In this review, we introduce the important roles of lncRNAs and circRNAs in some representative cancers, respectively. Furthermore, we focus on the biological functions and important clinical therapeutic implications of lnRNAs and circRNAs in neuroblastoma. Our review also focuses on providing rationale and relevant references for novel biomarkers for neuroblastoma diagnosis, prognosis, and treatment.
引用
收藏
页数:28
相关论文
共 300 条
[1]   PEDIATRIC BRAIN-TUMORS [J].
ALBRIGHT, AL .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (05) :272-288
[2]  
Alderton GK, 2011, NAT REV CANCER, V11, P627, DOI [10.1038/nrc3132, 10.1038/nrc3129]
[3]   Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes [J].
Almutairi, Bader ;
Charlet, Jessica ;
Dallosso, Anthony R. ;
Szemes, Marianna ;
Etchevers, Heather C. ;
Malik, Karim T. A. ;
Brown, Keith W. .
SCIENTIFIC REPORTS, 2019, 9 (1)
[4]   Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy? [J].
Ando, Kiyohiro ;
Nakagawara, Akira .
BIOMOLECULES, 2021, 11 (05)
[5]   Emerging therapeutic targets for neuroblastoma [J].
Aravindan, Natarajan ;
Herman, Terence ;
Aravindan, Sheeja .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (09) :899-914
[6]   Therapeutic Targeting of Long Non-Coding RNAs in Cancer [J].
Arun, Gayatri ;
Diermeier, Sarah D. ;
Spector, David L. .
TRENDS IN MOLECULAR MEDICINE, 2018, 24 (03) :257-277
[7]   SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p [J].
Bao, Juntao ;
Zhang, Shufeng ;
Meng, Qinglei ;
Qin, Tao .
NEUROCHEMICAL RESEARCH, 2020, 45 (04) :825-836
[8]   Pharmacology of Antisense Drugs [J].
Bennett, C. Frank ;
Baker, Brenda F. ;
Nguyen Pham ;
Swayze, Eric ;
Geary, Richard S. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 :81-105
[9]   RNAi screens in mice identify physiological regulators of oncogenic growth [J].
Beronja, Slobodan ;
Janki, Peter ;
Heller, Evan ;
Lien, Wen-Hui ;
Keyes, Brice E. ;
Oshimori, Naoki ;
Fuchs, Elaine .
NATURE, 2013, 501 (7466) :185-+
[10]  
Bi LL, 2018, EUR REV MED PHARMACO, V22, P4204, DOI 10.26355/eurrev_201807_15414